attyloid is a spin-off from Forschungszentrum Jülich and Heinrich-Heine University Düsseldorf. attyloid offers its proprietary sFIDA platform technology for the ultrasensitive quantitation of protein particles. The ISO9001:2015-embedded sFIDA technology is fully automized and scalable. Building on a strong scientific expertise in protein misfolding and aggregation, we focus our business model on biomarker-based diagnostics of CNS diseases and aggregate quantitation in biologicals. attyloid offers sFIDA to pharmaceutical and biotech companies.
sFIDA stands for surface-based fluorescence intensity distribution analysis. The assay uses a combination of aggregate-binding antibodies and fluorescence microscopy imaging. First, protein aggregates are captured from the sample and fixed to a glass sur- face. After unbound sample components are removed, detection antibodies labeled with two fluorescent dyes are added. A laser focus scans the surface and the highly decorated aggregates show bursts of fluorescent light in two color channels.
sFIDA allowed clear differentiation between samples from diseased and healthy donors. Moreover, the readout correlated with the severity of cognitive deficits. The assay is currently in the process of validation and optimization for the demands of high-throughput measurements. MORE
attyloid draws on a strong team of founders with expertise in Life Science, Health Care and Corporate Development.
Dr. Oliver Bannach
Dr. Andreas Kulawik
Dr. Christian Zafiu
Prof. em. Dr. Dr. h.c. Detlev Riesner
Prof. Dr. Dieter Willbold
Supervisory Board Chairman
Get in Touch
Fon: +49 (0) 211 81-10377